论文部分内容阅读
目的观察博利康尼和必可酮联合使用对小儿哮喘气道炎症影响,为防治哮喘提供理论依据。方法将过敏性哮喘患儿60例随机分为3组,必可酮组:吸入必可酮250μg/次,2次/d;博利康尼组:给予博利康尼0.1mg/kg,3次/d口服;观察组:同时给予必可酮和博利康尼,剂量同前,但必可酮在口服博利康尼后20min再吸入。各组疗程均为7d,各组患儿在治疗前对外周血测定白细胞总数和分类计数;然后给予3%氯化钠溶液10ml雾化吸入后诱导痰液,测定痰液白细胞总数以及痰液涂片进行细胞分类。结果必可酮组、博利康尼组患儿治疗后其临床症状均有不同程度的缓解,有效率分别为87.5%、72.2%,观察组患儿的症状迅速缓解,有效率100%,3组患儿治疗前、后外周血白细胞总数和分类均差异均为无统计学意义。观察组治疗后炎性反应细胞总数及分类计数明显低于博利康尼组和必可酮组(P<0.05)。结论口服博利康尼片后能在一定程度上改善哮喘患儿使用吸入糖皮质激素气雾剂的依从性,联合使用β受体激动剂和吸入糖皮质激素具有显著的协同抗炎作用。
Objective To observe the effect of combined use of boli and niacin on airway inflammation in pediatric asthma and to provide a theoretical basis for the prevention and treatment of asthma. Methods 60 children with allergic asthma were randomly divided into 3 groups: beclomethazone group: inhaled becciclovir 250μg / time, twice a day; d oral; observation group: given both ketoconazole and beverine, with the same dose, but after the oral administration of beceridone beclomethalide again 20min. Each treatment group were 7d, each group of children in the treatment of peripheral blood leukocytes and count the total count; then given 3% sodium chloride solution 10ml inhalation induced sputum, the total number of sputum leukocytes and sputum smear Tablet for cell classification. Results After treatment, the clinical symptoms of patients in the beclomethazone group and the group of beconidiine group were all relieved to varying degrees, with the effective rates of 87.5% and 72.2%, respectively. The symptoms of the observation group were relieved rapidly and the effective rate was 100%. The three groups Children before and after treatment, the total number and classification of peripheral white blood cells were no significant difference. The total number of inflammatory cells and the number of inflammatory cells in the observation group were significantly lower than those in the group of BoliCan and Berberine (P <0.05). Conclusions Oral administration of beclomecisini tablet can improve the compliance of inhaled glucocorticosteroid aerosol in children with asthma to a certain extent. The combination of beta-agonist and inhaled glucocorticosteroid has significant synergistic anti-inflammatory effect.